Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial

Table 4 The effect of L-NMMA on components of the renin-angiotensin system and plasma levels of sodium and potassium after six weeks of paricalcitol treatment (n = 26)

	Baseline	60 min	120 min	P _Within	P _Between
PRC (pg/ml)
Placebo	10.4 [6.1;23.6]	10.1 [6.1;18.8]	8.2 [6.8;17.1]	0.02 <0.01	0.31
Paricalcitol	10.9 [6.4;25.2]	8.4 [5.7;18.3]	8.9 [6.5;19.3]		0.31
p-AngII (pg/ml)
Placebo	5.0 [8.0;12.0]	6.5 [4.0;12.0]	7.5 [5.0;9.0]	0.01	0.17
Paricalcitol	8.0 [5.0;15.0]	7.0 [5.0;12.0]	8.0 [4.5;12.0]	<0.01	0.17
p-Aldo (pmol/l)
Placebo	287 [152;607]	376 [180;663]	302 [161;520]	<0.01	0.24
Paricalcitol	335 [187;619]	346 [200;742]	282 [165;590]	<0.01	0.24
p-K (mmol/l)
Placebo	4.0 [3.7;4.4]	3.9 [3.7;4.4]	3.9 [3.7;4.4]	0.96	0.19
Paricalcitol	3.8 [3.6;4.2]*	3.7 [3.6;4.2]	3.8 [3.6;4.2]	0.80	0.19
p-Na (mmol/l)
Placebo	138 [136;140]	138 [136;138]	137 [135;140]	0.76	0.33
Paricalcitol	138 [136;140]	138 [136;140]	138 [136;140]	0.33	0.33
p-BNP (pmol/l)
Placebo	8.1[4.4;19.5]	-	-
Paricalcitol	7.5[4.8;14.3]	-	-
p-AVP (pg/ml)
Placebo	0.5 [0.4;0.7]	-	-
Paricalcitol	0.5 [0.4;0.7]	-	-

Values are medians with 25 and 75 percentiles in brackets. L-NMMA, NG-monomethyl-L-arginine; PRC, plasma renin concentration; AngII, angiotensin II; Aldo, aldosterone; K, potassium; Na, sodium; BNP, brain natriuretic peptide; AVP, vasopressin. L-NMMA infusion was sustained for 60 minutes. P_within represents the probability of an effect of NOS inhibition after each treatment assessed by Friedman’s ANOVA. P_between represents the probability that paricalcitol alters the response to L-NMMA assessed by a general linear model for repeated measures with treatment as factor.
* = p < 0.05 vs. placebo at baseline.

ISSN: 1471-2369